单药本妥昔单抗作为严重肝功能损害的霍奇金淋巴瘤患者的一线治疗：两例报告 - Suppr | 超能文献

相似文献

1

Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.单药本妥昔单抗作为严重肝功能损害的霍奇金淋巴瘤患者的一线治疗：两例报告

Ann Hematol. 2023 Oct;102(10):2973-2975. doi: 10.1007/s00277-023-05390-4. Epub 2023 Jul 31.

2

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?本妥昔单抗维迪西妥单抗在霍奇金淋巴瘤患者的治疗管理中处于什么位置？

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.

3

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.在未经移植的复发或难治性霍奇金淋巴瘤患者中应用 Brentuximab vedotin：两项 I 期研究的分析。

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

4

Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.本妥昔单抗致淋巴瘤患者胰腺炎：一项药物警戒研究。

Leuk Lymphoma. 2022 Jul;63(7):1768-1769. doi: 10.1080/10428194.2022.2045601. Epub 2022 Mar 6.

5

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.本妥昔单抗治疗霍奇金淋巴瘤的安全性评估。

Expert Opin Drug Saf. 2016 Jun;15(6):875-82. doi: 10.1080/14740338.2016.1179277. Epub 2016 May 5.

6

Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.一线使用本妥昔单抗治疗经典型霍奇金淋巴瘤后发生的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤

Ann Hematol. 2022 May;101(5):1149-1152. doi: 10.1007/s00277-021-04709-3. Epub 2021 Nov 10.

7

Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.与维布妥昔单抗治疗相关的严重进行性鸟分枝杆菌复合群感染

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.

8

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.本妥昔单抗维达汀不会导致 CD30 阳性血液恶性肿瘤患者出现临床相关的 QTc 间期延长。

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

9

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.自体造血干细胞移植后博纳吐珠单抗联合纳武利尤单抗治疗高危经典型霍奇金淋巴瘤成人患者的多中心、2 期临床试验。

Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17.

10

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.在复发或难治性 CD30 阳性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤的日本患者中进行 brentuximab vedotin 的 I/II 期研究。

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

引用本文的文献

1

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.本妥昔单抗单药治疗伴有HTLV-1感染的霍奇金和里德-斯腾伯格样细胞的CD30阳性成人T细胞白血病/淋巴瘤。

J Clin Exp Hematop. 2025;65(2):140-145. doi: 10.3960/jslrt.25019.

本文引用的文献

1

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.本妥昔单抗联合化疗治疗Ⅲ期或Ⅳ期经典型霍奇金淋巴瘤（ECHELON-1）：一项国际、开放标签、随机、3期试验的5年随访结果

Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2.

2

Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.在多次复发/难治性经典型霍奇金淋巴瘤中，维布妥昔单抗成功逆转严重肝功能损害。

J BUON. 2019 Nov-Dec;24(6):2483-2489.

3

Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment.